Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study

Summary Lymphoplasmacytic lymphoma (LPL) not fulfilling the WHO diagnostic criteria (2017) for Waldenstrom’s macroglobulinemia (WM) (named non‐WM LPL) is a rare disease and only a few systematic studies have been published. Here, we present a population‐based study of non‐WM LPL focusing on diagnost...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:British journal of haematology Ročník 196; číslo 6; s. 1362 - 1368
Hlavní autoři: Brandefors, Lena, Sander, Birgitta, Lundqvist, Kristina, Kimby, Eva
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Blackwell Publishing Ltd 01.03.2022
Témata:
clinical aspects
Diagnosis
epidemiology
Hematology
Humans
Immunoglobulin A
Immunoglobulin G
Lymphocytosis
Lymphoma
Lymphoma, B-Cell
lymphoplasmacytic lymphoma
Macroglobulinemia
Medical prognosis
Medical treatment
Patients
Population studies
Rare diseases
Registries
risk factors
Survival
Sweden - epidemiology
Waldenstrom Macroglobulinemia - drug therapy
Sweden
epidemiology
clinical aspects
risk factors
lymphoplasmacytic lymphoma
ISSN:0007-1048, 1365-2141, 1365-2141
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Summary Lymphoplasmacytic lymphoma (LPL) not fulfilling the WHO diagnostic criteria (2017) for Waldenstrom’s macroglobulinemia (WM) (named non‐WM LPL) is a rare disease and only a few systematic studies have been published. Here, we present a population‐based study of non‐WM LPL focusing on diagnostic difficulties, patient characteristics, and outcome. From 1511 patients included in the Swedish Lymphoma Registry 1 Jan 2000 – 31 Dec 2014 with a diagnosis of WM/LPL, we could confirm the diagnosis of non‐WM LP in only 33 patients. The median age at diagnosis was 69 years. A paraprotein was found in most (IgG in 54%, IgA in 15%) and 12% of the cases were non‐secretory. Compared with the WM patients, the non‐WM LPL patients were younger, had more adverse prognostic factors such as elevated LDH, anaemia, and lymphocytosis at diagnosis. In addition, the non‐WM LPL patients more often were symptomatic and received treatment at diagnosis. The overall survival (OS) did not significantly differ between the non‐WM LPL and WM groups (P = 0.247), with a median survival time of 71 and 96 months, respectively. To conclude, we found differences in clinical features between WM and non‐WM LPL, but no difference in survival.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/bjh.18002